Wei Cai and Bo Jian: The maintenance dosing regimen of Exelon has been approved in China for the treatment of early Alzheimer's disease.

On September 29th, Weicai and Bojian announced that their humanized anti-soluble amyloid beta monoclonal antibody lunakann monoclonal antibody, which is administered intravenously every four weeks as a maintenance dose regimen, has been approved by the China National Medical Products Administration.